<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38566450</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-3907</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>02</Day></PubDate></JournalIssue><Title>Journal of proteome research</Title><ISOAbbreviation>J Proteome Res</ISOAbbreviation></Journal><ArticleTitle>Reinforcing the Evidence of Mitochondrial Dysfunction in Long COVID Patients Using a Multiplatform Mass Spectrometry-Based Metabolomics Approach.</ArticleTitle><Pagination><StartPage>3025</StartPage><EndPage>3040</EndPage><MedlinePgn>3025-3040</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jproteome.3c00706</ELocationID><Abstract><AbstractText>Despite the recent and increasing knowledge surrounding COVID-19 infection, the underlying mechanisms of the persistence of symptoms for a long time after the acute infection are still not completely understood. Here, a multiplatform mass spectrometry-based approach was used for metabolomic and lipidomic profiling of human plasma samples from Long COVID patients (<i>n</i> = 40) to reveal mitochondrial dysfunction when compared with individuals fully recovered from acute mild COVID-19 (<i>n</i> = 40). Untargeted metabolomic analysis using CE-ESI(+/-)-TOF-MS and GC-Q-MS was performed. Additionally, a lipidomic analysis using LC-ESI(+/-)-QTOF-MS based on an in-house library revealed 447 lipid species identified with a high confidence annotation level. The integration of complementary analytical platforms has allowed a comprehensive metabolic and lipidomic characterization of plasma alterations in Long COVID disease that found 46 relevant metabolites which allowed to discriminate between Long COVID and fully recovered patients. We report specific metabolites altered in Long COVID, mainly related to a decrease in the amino acid metabolism and ceramide plasma levels and an increase in the tricarboxylic acid (TCA) cycle, reinforcing the evidence of an impaired mitochondrial function. The most relevant alterations shown in this study will help to better understand the insights of Long COVID syndrome by providing a deeper knowledge of the metabolomic basis of the pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centro de Metabol&#xf3;mica y Bioan&#xe1;lisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities. Urbanizaci&#xf3;n Montepr&#xed;ncipe, 28660 Boadilla del Monte, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alb&#xf3;niga</LastName><ForeName>Oihane E</ForeName><Initials>OE</Initials><AffiliationInfo><Affiliation>Centro de Metabol&#xf3;mica y Bioan&#xe1;lisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities. Urbanizaci&#xf3;n Montepr&#xed;ncipe, 28660 Boadilla del Monte, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asociaci&#xf3;n Centro de Investigaci&#xf3;n Cooperativa en Biociencias (CICbioGUNE), Bizkaia Science and Technology Park bld 800, 48160 Derio, Bizkaia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Huertas</LastName><ForeName>Mar&#xed;a Rosa</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Unidad de Inmunopatolog&#xed;a del SIDA, Centro Nacional de Microbiolog&#xed;a, Instituto de Salud Carlos III, 28220 Majadahonda, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gradillas</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Metabol&#xf3;mica y Bioan&#xe1;lisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities. Urbanizaci&#xf3;n Montepr&#xed;ncipe, 28660 Boadilla del Monte, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbas</LastName><ForeName>Coral</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4722-491X</Identifier><AffiliationInfo><Affiliation>Centro de Metabol&#xf3;mica y Bioan&#xe1;lisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities. Urbanizaci&#xf3;n Montepr&#xed;ncipe, 28660 Boadilla del Monte, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Proteome Res</MedlineTA><NlmUniqueID>101128775</NlmUniqueID><ISSNLinking>1535-3893</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002518">Ceramides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="Y">Metabolomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="Y">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081362" MajorTopicYN="Y">Lipidomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="N">Metabolome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002952" MajorTopicYN="N">Citric Acid Cycle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002518" MajorTopicYN="N">Ceramides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CE-ESI(+/&#x2212;)-TOF-MS</Keyword><Keyword MajorTopicYN="N">GC-Q-MS</Keyword><Keyword MajorTopicYN="N">RP-UHPLC-ESI(+/&#x2212;)-QTOF-MS</Keyword><Keyword MajorTopicYN="N">ceramides</Keyword><Keyword MajorTopicYN="N">lipidomic</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">metabolomic</Keyword><Keyword MajorTopicYN="N">mitochondrial dysfunction</Keyword><Keyword MajorTopicYN="N">post-COVID syndrome (PCS)</Keyword><Keyword MajorTopicYN="N">tricarboxylic acid (TCA) cycle</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>3</Day><Hour>1</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38566450</ArticleId><ArticleId IdType="doi">10.1021/acs.jproteome.3c00706</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>